Health and Medicine
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
Sep. 16, 2021—Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.
Sep. 16, 2021—Vanderbilt's Cecilia Chung, MD, MPH, has received the 2022 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics (ASCPT).
Sep. 10, 2021—Vanderbilt researchers have identified a new antibacterial mechanism that could inspire novel strategies for combating staph and other extracellular bacterial pathogens.
Sep. 10, 2021—Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
Sep. 8, 2021—Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.